The global non-invasive prenatal testing (NIPT) market is forecast to grow at a CAGR of 17.44% during the period 2016-2020.
Commenting on the report, an analyst from the research team said: Increase in partnerships and collaborations will be a challenge for the market. Vendors enter into partnerships and collaborations to extend their product offerings, increase their market shares, and expand their operations. These partnerships and collaborations help vendors enhance their R&D capabilities for manufacturing innovative devices that meet consumer needs. For instance, in 2015, Human Longevity entered into a partnership with Roche Diagnostics to conduct whole-genome sequencing of Roche Diagnostics' subsidiary Genentech's de-identified samples.
The partnership helped Roche Diagnostics analyze patient samples based on precise genetic categories and discover new diagnostics and targeted therapies. In 2011, Natera formed a partnership with DNA Diagnostics Center to enter the market. These partnerships and collaborative activities are accelerating drug discovery efforts, which will lead to the development of new therapies to detect chromosomal abnormalities in neonates.
According to the report, the number of neonates with chromosomal disorders is on the rise worldwide due to rapid urbanization, child-bearing at an advanced maternal age, pollution, and increased consumption of alcohol consumption. This factor will be a key driver for market growth. A few conventional procedures such as chorionic villus sampling and amniocentesis that help detect chromosomal defects in developing fetuses are available in the market.
However, these tests have high chances of causing miscarriage, restricting people from undergoing them. This unmet need led to the development of new advanced prenatal tests that are invasive and have no risks of miscarriage. Vendors are also developing NIPTs that have high accuracy result and lower side effects for use in hospitals and nursing homes.
- What will the market size be in 2020 and what will the growth rate be?
- What are the key market trends?
- What is driving this market?
- What are the challenges to market growth?
- Who are the key vendors in this market space?
- What are the market opportunities and threats faced by the key vendors?
- What are the strengths and weaknesses of the key vendors?
- BGI Genomics
- Ariosa Diagnostics
- Berry Genomics
- F. Hoffmann-La Roche
- Genpharm Services
- Laboratory Corporation of America Holdings
- LifeLabs Genetics
- Quest Diagnostics
PART 01: Executive summary
PART 02: Scope of the report
PART 03: Market research methodology
PART 04: Introduction
PART 05: Market landscape
PART 06: Market segmentation by testing product
PART 07: Market segmentation by end-user
PART 08: Geographical segmentation
PART 09: Market drivers
PART 10: Impact of drivers
PART 11: Market challenges
PART 12: Impact of drivers and challenges
PART 13: Market trends
PART 14: Vendor landscape
PART 15: Major vendors
PART 16: Appendix
PART 17: About the Author
For more information about this report visit http://www.researchandmarkets.com/research/vt4hv2/global
Related Topics: Women's Health
Research and Markets
Laura Wood, Senior Manager
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/research-and-markets---global-non-invasive-prenatal-testing-market-cagr-growth-of-1744-by-2020---trends-technologies--opportunities-report-2016-2020---key-vendors-berry-genomics-natera-safembryo-300329355.html
SOURCE Research and Markets